Clinical Trial

A Phase 3 Clinical Study of QL2106 Injection

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2106 injection orTremfya®
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-06
Trial Details
NCT Number NCT07511647
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Plaque Psoriasis
Enrollment 318 participants
Start Date 2026-06-15
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-05